They were the first to develop and market 3-D imaging technology to vascular surgeons. Based on research conducted in the laboratory of the companys founding scientist, Tim Springer, Morphic is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders and immune-oncology. Several programs are advancing towards clinical development. The company has developed comprehensive technology platforms and expertise around drug discovery assays, assay development, high throughput drug screening, and hit-to-lead biology. 
IPO 2013. Assets sold to Medivir in Dec 2016. It is being developed as a potential best-in-class therapeutic for the treatment of short bowel syndrome. 
Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. HD Biosciences customers include Pfizer and several other large pharmaceutical companies. The company was spun out of Cambridge University, translating the ground-breaking research of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into first-in-class drugs in oncology and other diseases. Songwriters, poets, and novelists have long tried to capture the intricacies of the heart. Anjarium Biosciences, strives to create and deliver solutions for patients beyond what current gene therapy platforms address today. Ahn K, Boehm M, Brown MF, Calloway J, Che Y, Chen J, Fennell KF, Geoghegan KF, Gilbert AM, Gutierrez JA, Kalgutkar AS, Lanba A, Limberakis, Magee TV, O'Doherty I, Oliver R1,2, Pabst B1,2, Pandit J, Parris K, Pfefferkorn JA, Rolph TP, Patel R, Schuff B, Shanmugasundaram V, Starr JT, Varghese AH, Vera NB, Vernochet C, Yan J. Garfield AS, Shah BP, Burgess CR, Li MM, Li C, Steger JS, Madara JC, Campbell JN, Kroeger D, Scammell TE, Tannous BA, Myers Jr. MG, Andermann ML, Krashes MJ, Lowell BB. 
Ixchelsis Limited is an independent biotechnology company based in Discovery Park, Sandwich, UK. Talukdar T, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Chabot JR, Erion DM, Rolph TP, Goodwin B, and Calle RA. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets which are expressed on multiple immune cell types, with the aim to generate first-in-class treatments for unmet needs in oncology and autoimmune diseases. Provider of pharmaceutical supply chain security solutions to pharmaceutical companies and their trading partners seeking to enhance product integrity and supply chain efficiency. The companys lead compounds are ZPL-389, an oral histamine H4 receptor antagonist entering Phase 2 studies for atopic dermatitis and ZPL-521, a cPLA-2 inhibitor being advanced for psoriasis. 
BioAtla develops novel monoclonal antibody and cell-based immunotherapies with improved therapeutic index for the treatment of cancer. Were committed to addressing these global health challenges by developing potential therapies to treat or prevent disease progression and improve the quality of life for patients. The companys lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of disproportionate short stature in humans. Triplet is developing RNA therapeutics to precisely knock down key components of the DDR pathway that drive repeat expansion across a wide range of disorders. The companys mission is to exploit these cellular interactions with therapeutics to drive and sustain immune reactions against solid tumors. Evolution Benefits (EB) offers innovative, integrated products for the employee benefits market. Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. Were turning advanced science and technologies into therapies that matter most. TRex Bio is a stealth mode, discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases. 
Additional studies are also planned in other major cancer indications. In 2004, they launched their first test under the brand name Oncotype DX for early stage breast cancer. We believe that a comprehensive program is needed to address the collection of diseases of the cardiovascular system, as well as their root causes, including obesity and metabolic disease. FoRx is developing first-in-class small-molecule therapeutics that exploit the presence of DNA replication stress in human cancers. The company has created a turnkey solution to drive the discovery of a diversified portfolio of drugs, thereby expediting the search for medicines that will better treat a wide spectrum of diseases. The companys lead product candidate, XMT1522, is in Phase I clinical trials and the second product candidate, XMT1536, will be entering clinical trials in early 2018. This includes more targeted potential therapies, as well as possible therapies that are a combination of two or more drugs, which could bring additional benefits to patients. Montis is a biotech company targeting perivascular macrophages, a subpopulation of macrophages that interact with the endothelial cells of the vasculature. Our ambitions are big and our product pipeline has never been stronger. The qualities you demonstrated as a member of the armed forces are most welcome at Pfizer. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. As the potential threat of COVID-19 became clear by early 2020, teams across Pfizer sprang into action. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. CVD continues as an epidemic, driven by a number of factors, including the rising rates of obesity and its resulting metabolic diseases, such as type 2 diabetes mellitus and the metabolic syndrome, which refers to the group of risk factors that increase an individuals risk for heart disease and other health problems.2 The modern lifestyle has promoted a new array of cardiovascular risk factors, but treatments for these have remained elusive. 
These highly accurate measurements aid metabolic research and drug development in the challenging areas of obesity and its co-morbidities. By selectively amplifying active-form PINK1 activity, Mitokinin believes it can address the cellular pathologies underlying Parkinsons disease and ultimately slow or halt the progression of the disease. This includes more potential therapies targeted to specific metabolic pathways in the body, as well as therapies that are a combination of two or more drugs, which could bring additional benefits to patients. Explore all of our disease and condition-related resources to learn more about your diagnosis and treatment options. NeuroTherapeutics Pharma, Inc. (NTP) is focused on developing therapies for diseases associated with central nervous system hyper-excitability. 
NASH is preceded by an abnormal accumulation of lipid in the liver, a condition that is associated with obesity and insulin resistance and is estimated to impact as many as 30% of all adults in the US.4 Ultimately, NASH can lead to liver fibrosis, cirrhosis and eventually liver failure5 or cancer6, and has no approved treatment. In 2008, Aureon successfully launched their Px+ prostate biopsy test, which has already seen very rapid uptake in the market. Epic Sciences is focused on developing novel diagnostics to improve and personalize the treatment and management of cancer. LSACs rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. 
Anjarium is developing a new generation of genetic medicines to overcome the greatest challenges facing the field, notably immunogenicity, payload capacity, individualized multiple dosing, targeted delivery and scaled manufacturing. Despite fewer people smoking and effective therapies for hypertension and high cholesterol, cardiovascular disease (CVD) remains the number one cause of death worldwide.1, This epidemic is driven by demographic factors like an aging population, decreasing mortality from other factors (such as infectious disease), and rising rates of obesitywhich can drive the progression of metabolic diseases, such as Type 2 diabetes, and lead to the metabolic syndrome, a constellation of risk factors that increase an individuals risk for heart disease and other health problems.2-6. While Palleon is focused primarily on oncology, the platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. Accelerator NY is located at the Alexandria Center for Life Science in the heart of Manhattans East Side Medical Corridor. This new class of medicines, RNA-targeted small molecules (rSMs), will focus on new disease intervention points identified in the human transcriptome as well as valuable targets that are not accessible with todays medicines. Simcha Therapeutics is an early stage biopharmaceutical company with a focus on developing next generation cytokine immunotherapies to trigger the immune system to fight disease, particularly cancers. Each PhysioLab platform provides a framework for integrating data (e.g., genomic, proteomic, physiologic, environmental) in the context of a disease or therapeutic area, focusing on understanding and determining clinical responses to potential treatment. Accelerator New York is a leading life science investment vehicle supporting emerging biotechnology research. This epidemic is driven by demographic factors like an aging population, decreasing mortality from other factors (such as infectious disease), and rising rates of obesitywhich can drive the progression of metabolic diseases, such as Type 2 diabetes, and lead to the metabolic syndrome, a constellation of risk factors that increase an individuals risk for heart disease and other health problems. Consider that tobacco control has been identified as one of the most rational, evidence-based policies in medicine. Nodality, Inc. is an emerging biotechnology company focused on patient-specific classification of disease. Neuronetics is the leader in the development of NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation. The inReach system enables accurate and minimally invasive navigation anywhere in the lungs in real time and on a 3D CT roadmap, increasing both the success rate and applicability of diagnostic bronchoscopy. Using its protein degradation platform, the company is building a therapeutic pipeline in oncology and immunology.
IPO 2013. Assets sold to Medivir in Dec 2016. It is being developed as a potential best-in-class therapeutic for the treatment of short bowel syndrome. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. HD Biosciences customers include Pfizer and several other large pharmaceutical companies. The company was spun out of Cambridge University, translating the ground-breaking research of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into first-in-class drugs in oncology and other diseases. Songwriters, poets, and novelists have long tried to capture the intricacies of the heart. Anjarium Biosciences, strives to create and deliver solutions for patients beyond what current gene therapy platforms address today. Ahn K, Boehm M, Brown MF, Calloway J, Che Y, Chen J, Fennell KF, Geoghegan KF, Gilbert AM, Gutierrez JA, Kalgutkar AS, Lanba A, Limberakis, Magee TV, O'Doherty I, Oliver R1,2, Pabst B1,2, Pandit J, Parris K, Pfefferkorn JA, Rolph TP, Patel R, Schuff B, Shanmugasundaram V, Starr JT, Varghese AH, Vera NB, Vernochet C, Yan J. Garfield AS, Shah BP, Burgess CR, Li MM, Li C, Steger JS, Madara JC, Campbell JN, Kroeger D, Scammell TE, Tannous BA, Myers Jr. MG, Andermann ML, Krashes MJ, Lowell BB. Ixchelsis Limited is an independent biotechnology company based in Discovery Park, Sandwich, UK. Talukdar T, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Chabot JR, Erion DM, Rolph TP, Goodwin B, and Calle RA. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets which are expressed on multiple immune cell types, with the aim to generate first-in-class treatments for unmet needs in oncology and autoimmune diseases. Provider of pharmaceutical supply chain security solutions to pharmaceutical companies and their trading partners seeking to enhance product integrity and supply chain efficiency. The companys lead compounds are ZPL-389, an oral histamine H4 receptor antagonist entering Phase 2 studies for atopic dermatitis and ZPL-521, a cPLA-2 inhibitor being advanced for psoriasis. BioAtla develops novel monoclonal antibody and cell-based immunotherapies with improved therapeutic index for the treatment of cancer. Were committed to addressing these global health challenges by developing potential therapies to treat or prevent disease progression and improve the quality of life for patients. The companys lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of disproportionate short stature in humans. Triplet is developing RNA therapeutics to precisely knock down key components of the DDR pathway that drive repeat expansion across a wide range of disorders. The companys mission is to exploit these cellular interactions with therapeutics to drive and sustain immune reactions against solid tumors. Evolution Benefits (EB) offers innovative, integrated products for the employee benefits market. Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. Were turning advanced science and technologies into therapies that matter most. TRex Bio is a stealth mode, discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases. Additional studies are also planned in other major cancer indications. In 2004, they launched their first test under the brand name Oncotype DX for early stage breast cancer. We believe that a comprehensive program is needed to address the collection of diseases of the cardiovascular system, as well as their root causes, including obesity and metabolic disease. FoRx is developing first-in-class small-molecule therapeutics that exploit the presence of DNA replication stress in human cancers. The company has created a turnkey solution to drive the discovery of a diversified portfolio of drugs, thereby expediting the search for medicines that will better treat a wide spectrum of diseases. The companys lead product candidate, XMT1522, is in Phase I clinical trials and the second product candidate, XMT1536, will be entering clinical trials in early 2018. This includes more targeted potential therapies, as well as possible therapies that are a combination of two or more drugs, which could bring additional benefits to patients. Montis is a biotech company targeting perivascular macrophages, a subpopulation of macrophages that interact with the endothelial cells of the vasculature. Our ambitions are big and our product pipeline has never been stronger. The qualities you demonstrated as a member of the armed forces are most welcome at Pfizer. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. As the potential threat of COVID-19 became clear by early 2020, teams across Pfizer sprang into action. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. CVD continues as an epidemic, driven by a number of factors, including the rising rates of obesity and its resulting metabolic diseases, such as type 2 diabetes mellitus and the metabolic syndrome, which refers to the group of risk factors that increase an individuals risk for heart disease and other health problems.2 The modern lifestyle has promoted a new array of cardiovascular risk factors, but treatments for these have remained elusive. These highly accurate measurements aid metabolic research and drug development in the challenging areas of obesity and its co-morbidities. By selectively amplifying active-form PINK1 activity, Mitokinin believes it can address the cellular pathologies underlying Parkinsons disease and ultimately slow or halt the progression of the disease. This includes more potential therapies targeted to specific metabolic pathways in the body, as well as therapies that are a combination of two or more drugs, which could bring additional benefits to patients. Explore all of our disease and condition-related resources to learn more about your diagnosis and treatment options. NeuroTherapeutics Pharma, Inc. (NTP) is focused on developing therapies for diseases associated with central nervous system hyper-excitability. NASH is preceded by an abnormal accumulation of lipid in the liver, a condition that is associated with obesity and insulin resistance and is estimated to impact as many as 30% of all adults in the US.4 Ultimately, NASH can lead to liver fibrosis, cirrhosis and eventually liver failure5 or cancer6, and has no approved treatment. In 2008, Aureon successfully launched their Px+ prostate biopsy test, which has already seen very rapid uptake in the market. Epic Sciences is focused on developing novel diagnostics to improve and personalize the treatment and management of cancer. LSACs rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Anjarium is developing a new generation of genetic medicines to overcome the greatest challenges facing the field, notably immunogenicity, payload capacity, individualized multiple dosing, targeted delivery and scaled manufacturing. Despite fewer people smoking and effective therapies for hypertension and high cholesterol, cardiovascular disease (CVD) remains the number one cause of death worldwide.1, This epidemic is driven by demographic factors like an aging population, decreasing mortality from other factors (such as infectious disease), and rising rates of obesitywhich can drive the progression of metabolic diseases, such as Type 2 diabetes, and lead to the metabolic syndrome, a constellation of risk factors that increase an individuals risk for heart disease and other health problems.2-6. While Palleon is focused primarily on oncology, the platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. Accelerator NY is located at the Alexandria Center for Life Science in the heart of Manhattans East Side Medical Corridor. This new class of medicines, RNA-targeted small molecules (rSMs), will focus on new disease intervention points identified in the human transcriptome as well as valuable targets that are not accessible with todays medicines. Simcha Therapeutics is an early stage biopharmaceutical company with a focus on developing next generation cytokine immunotherapies to trigger the immune system to fight disease, particularly cancers. Each PhysioLab platform provides a framework for integrating data (e.g., genomic, proteomic, physiologic, environmental) in the context of a disease or therapeutic area, focusing on understanding and determining clinical responses to potential treatment. Accelerator New York is a leading life science investment vehicle supporting emerging biotechnology research. This epidemic is driven by demographic factors like an aging population, decreasing mortality from other factors (such as infectious disease), and rising rates of obesitywhich can drive the progression of metabolic diseases, such as Type 2 diabetes, and lead to the metabolic syndrome, a constellation of risk factors that increase an individuals risk for heart disease and other health problems. Consider that tobacco control has been identified as one of the most rational, evidence-based policies in medicine. Nodality, Inc. is an emerging biotechnology company focused on patient-specific classification of disease. Neuronetics is the leader in the development of NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation. The inReach system enables accurate and minimally invasive navigation anywhere in the lungs in real time and on a 3D CT roadmap, increasing both the success rate and applicability of diagnostic bronchoscopy. Using its protein degradation platform, the company is building a therapeutic pipeline in oncology and immunology.